CTOs on the Move

Provectus Biopharmaceuticals

www.provectusbio.com

 
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus` investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Bruce Horowitz
Chief Operating Officer Profile

Similar Companies

Gnosko Bio

Gnosko Bio is a medical and laboratory supply company based in Philadelphia, PA that provides real-time inventory management automation solutions for the biotech industry.

Recruitech International

Recruitech International is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evotec

Evotec is a Winchester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aphria

Founded in 2013, Aphria is integrating their growing expertise with Health Canada`s new Access to Cannabis for Medical Purposes Regulations (ACMPR) for the medicinal marijuana industry. Possessing greenhouse related growing experience in plant and produce related expertise since 1943, Aphria is positioned to be an industry leader in providing patients with the highest quality medical marijuana. Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit. Aphria is a licensed producer of Medicinal Marijuana under the Health Canada Regulations. Grown in Greenhouses, Aphria offers premium medical grade cannabis. Located in Leamington in Southwestern Ontario, the heart of the greenhouse-producing sector for plant and produce, Aphria is built from a lengthy background of greenhouse growing and business experience.

Cytovia Therapeutics

Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.